Great expectations: the urgent need for common purpose in Alzheimer’s disease

Is it time for a more integrated and human-centric approach to Medical Affairs leadership?

By Shairose Ebrahim

Rare disease trials Q&A

Lonely planet: why there is dwindling value in pharma travelling alone

Accelerating diagnosis in rare disease

Biopharmaceutical companies can drive effective partnerships and improve outcomes for all stakeholders and patients in the area of rare disease.

Accelerating innovation

Ipsen’s Alexandre Lebeaut on the French firm’s oncology plans, global focus and R&D approach

Janssen’s quest to prevent diseases taking hold

Johan van Hoof, general manager of Janssen Vaccines & Prevention, on 'recalibrating' public understanding of illness